Securities code: Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) securities abbreviation: Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) Announcement No.: 2022039 Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693)
Announcement of abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Introduction to abnormal fluctuations in stock trading
Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) (hereinafter referred to as “the company” and “the company”) (Securities abbreviation: Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) , securities code: Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) ) the stock trading price deviated from the closing price for three consecutive trading days on April 27, 2022, April 28, 2022 and April 29, 2022 by 22.87%. According to the relevant provisions of Shenzhen Stock Exchange, it belongs to abnormal fluctuations in stock trading.
2、 The company pays attention to and verifies relevant information
In view of the abnormal fluctuation of the company’s shares, the company checked the relevant matters and inquired the controlling shareholder and actual controller of the company. The relevant information is as follows:
1. The information disclosed in the previous period does not need to be corrected or supplemented.
2. The company has not found any unpublished material information that may or has had a great impact on the company’s stock trading price reported by the public media recently.
3. Recently, the company’s business situation and internal and external business environment have not changed significantly.
4. After verification, the company, the controlling shareholder and the actual controller do not have any major events that should be disclosed but not disclosed about the company, nor do they have any major events in the planning stage.
5. After verification, the controlling shareholder and actual controller of the company did not buy or sell the company’s shares during the abnormal fluctuation of the company’s stock trading.
6. Through self-examination, the company does not violate the fair disclosure of information.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company has no undisclosed matters that should be disclosed according to the stock listing rules of Shenzhen Stock Exchange or planning, negotiation, intention, agreement, etc. related to the matters; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange and has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Necessary risk tips
1. After self-examination, the company did not violate the fair disclosure of information.
2. The company disclosed the performance forecast for the first quarter of 2022 on April 15, 2022. The performance forecast for the first quarter of 2022 is expected to realize a net profit of 550000 yuan to 800000 yuan attributable to the shareholders of the listed company. As of the disclosure date of this announcement, there is no significant difference between the data disclosed in the company’s performance forecast and the actual situation. The first quarter report of 2022 of the company was disclosed in the designated information disclosure media on April 30, 2022. The net profit attributable to the shareholders of the listed company in the first quarter of 2022 was 730100 yuan.
3. The company solemnly reminds investors: China Securities Journal, securities times and cninfo (www.cn. Info. Com. CN.) For the information disclosure media selected by the company, all information of the company shall be subject to the information published in the above designated media. The company will conscientiously perform the obligation of information disclosure and do a good job of information disclosure in a timely manner in strict accordance with the provisions and requirements of relevant laws and regulations. Please invest rationally and pay attention to risks. It is hereby announced!
Hainan Shuangcheng Pharmaceuticals Co.Ltd(002693) board of directors April 29, 2022
